NuGen Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - August 4, 2023) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") is pleased...
Pharmaceutical
Virogentics, Inc. Provides Update on African Project, European Medicine Agency Application and Clinical Trials for Application for Type 2 Diabetes
Progress on Sagaliam Acquisition Corp TransactionALLEN, TX / ACCESSWIRE / August 4, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Virogentics, Inc....
Universe Pharmaceuticals INC Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares
Jiangxi, China, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical...
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement and Reduce the Public Float
Common Stock Will Begin Trading on Split-Adjusted Basis on August 7, 2023CHARLOTTESVILLE, Va., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adial...
Intra-Cellular Therapies to Present at the Canaccord Genuity 43rd Annual Growth Conference
NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development...
Faron Pharmaceuticals Notice of Half-Year Financial Results
TURKU, Finland and BOSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical...
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
Completed single ascending dose (SAD) portion of Phase 1 trial evaluating OV329, a potential next-generation GABA-aminotransferase inhibitor Executed equity investment...
Recce Pharmaceuticals Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives
SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new...
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-- Actively enrolling patients in CHASE Phase 2b clinical trial of KPI-012 for the treatment of PCED; topline data targeted...
Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results
SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage...
Medexus to Participate in Fireside Chat at SHARE Series Event
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 4, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to...
Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), the first and only IL-23 receptor...
Veterinary Growth Partners Teams Up With PureWay to Advance Safe and Sustainable Compliance Services
PureWay Compliance, Inc. and Veterinary Growth Partners combine forces to address real issues regarding improperly managed waste and sustainability in...
Jaguar Health to Present Aug 4th at Wall Street Wonders Investment Group Luncheon in NYC
SAN FRANCISCO, CA / ACCESSWIRE / August 3, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the...
CNS Pharmaceuticals to Present at Benzinga’s Virtual Biotech Conference
Live moderated webcast fireside chat on August 3rd at 11:35 AM ETHOUSTON, TX / ACCESSWIRE / August 3, 2023 /...
CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Company continued to see rapid progression and acceleration of enrollment with 180 patients enrolled to date across 46 clinical trial...
Sonoma Pharmaceuticals Announces Appointment of Hye Jin Chung, M.D. to Scientific Advisory Board
BOULDER, CO / ACCESSWIRE / August 3, 2023 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing...
Bausch Health Announces Second-Quarter 2023 Results, Other Key Updates From the Quarter, and Raises Full-Year 2023 Revenue Outlook
Favorable Motion Ruling in Xifaxan® Litigation Reinforces Continuing Salix Growth StrategyBalance Sheet Initiatives Further Enhance Liquidity ProfileContinued Evaluation of Optimal...
Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates
Second quarter 2023 revenues of $0.3 billion; net loss of $1.4 billion and loss per share of $3.62Company expecting 2023...
Elevar Therapeutics to Host August 10 Virtual KOL Event on Phase 3 Study of Rivoceranib in Combination with Camrelizumab in Unresectable Hepatocellular Carcinoma (uHCC)
FORT LEE, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and...